
In an effort to clarify any misinterpretations of previous statements, the American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM), along with other medical and clinician groups, issued an update regarding the use of Makena (Ther-Rx Corporation; Bridgeton, Missouri) and compounded 17a-hydroxyprogesterone caproate (17P).
